Abstract
Background: Inflammation plays a significant role in the pathophysiology of Acute Coronary Syndrome (ACS) but is not included in current risk stratification.
Objective: This study aimed at determining the association between Thrombolysis in Myocardial Infarction (TIMI) risk score and inflammatory biomarkers in the ACS, including unstable angina (UA), Non-ST Segment Elevation Myocardial Infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). We hypothesized that inflammatory biomarkers could add prognostic value to the TIMI risk score.
Methods: In this cross-sectional study, serum levels of interleukins (IL)-6 and IL-1β and MDA (malondialdehyde) were quantified by ELISA and colorimetry, respectively, of patients with ACS (n = 48; 31.3 % with UA, 33.3 % with NSTEMI, and 35.4 % with STEMI) and healthy controls (n = 43). We assessed the TIMI scores in the first 24 h after symptom onset.
Results: The results showed that patients with ACS had significantly higher levels (p<0.05) of the inflammatory biomarkers IL-6, IL-1β, and MDA than the control group. However, we found no significant differences in IL-6, IL-1β, and MDA levels among the patients with ACS according to their classification as UA, NSTEMI, and STEMI. Positive correlations were observed between TIMI and IL-6 (r=0.68), IL-1β (r= 0.53), and MDA (r=0.58) in patients with UA and between TIMI and IL-1β (r= 0.62) in STEMI patients.
Conclusion: These data suggested the presence of a pro-inflammatory profile in patients with ACS as well as positive correlations between TIMI scores and the inflammatory biomarkers IL-6, IL-1β, and MDA in patients with UA and between TIMI scores and IL-1β in patients with STEMI. Combining inflammatory biomarkers with the TIMI risk score could provide better insight into the processes involved in ACS.
Keywords: Acute coronary syndrome, TIMI, IL-6, IL-1β, MDA, inflammation.
Recent Advances in Inflammation & Allergy Drug Discovery
Title:IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome
Volume: 15 Issue: 2
Author(s): Marcus V. de Paula da Silva, Pedro Henrique Villar-Delfino, José A. Nogueira-Machado and Caroline M.O. Volpe*
Affiliation:
- Faculdade Santa Casa BH, Programa de Pós-Graduação em Medicina-Biomedicina, Hospital Santa Casa de Belo Horizonte, Minas Gerais, Brazil
Keywords: Acute coronary syndrome, TIMI, IL-6, IL-1β, MDA, inflammation.
Abstract:
Background: Inflammation plays a significant role in the pathophysiology of Acute Coronary Syndrome (ACS) but is not included in current risk stratification.
Objective: This study aimed at determining the association between Thrombolysis in Myocardial Infarction (TIMI) risk score and inflammatory biomarkers in the ACS, including unstable angina (UA), Non-ST Segment Elevation Myocardial Infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). We hypothesized that inflammatory biomarkers could add prognostic value to the TIMI risk score.
Methods: In this cross-sectional study, serum levels of interleukins (IL)-6 and IL-1β and MDA (malondialdehyde) were quantified by ELISA and colorimetry, respectively, of patients with ACS (n = 48; 31.3 % with UA, 33.3 % with NSTEMI, and 35.4 % with STEMI) and healthy controls (n = 43). We assessed the TIMI scores in the first 24 h after symptom onset.
Results: The results showed that patients with ACS had significantly higher levels (p<0.05) of the inflammatory biomarkers IL-6, IL-1β, and MDA than the control group. However, we found no significant differences in IL-6, IL-1β, and MDA levels among the patients with ACS according to their classification as UA, NSTEMI, and STEMI. Positive correlations were observed between TIMI and IL-6 (r=0.68), IL-1β (r= 0.53), and MDA (r=0.58) in patients with UA and between TIMI and IL-1β (r= 0.62) in STEMI patients.
Conclusion: These data suggested the presence of a pro-inflammatory profile in patients with ACS as well as positive correlations between TIMI scores and the inflammatory biomarkers IL-6, IL-1β, and MDA in patients with UA and between TIMI scores and IL-1β in patients with STEMI. Combining inflammatory biomarkers with the TIMI risk score could provide better insight into the processes involved in ACS.
Export Options
About this article
Cite this article as:
de Paula da Silva V. Marcus, Villar-Delfino Pedro Henrique, Nogueira-Machado José A. and Volpe M.O. Caroline*, IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome, Recent Advances in Inflammation & Allergy Drug Discovery 2021; 15 (2) . https://dx.doi.org/10.2174/2772270816666220211091231
DOI https://dx.doi.org/10.2174/2772270816666220211091231 |
Print ISSN 2772-2708 |
Publisher Name Bentham Science Publisher |
Online ISSN 2772-2716 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer’s Disease
Current Aging Science Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets
Current Drug Targets Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation
Current Pharmaceutical Design Treatment of Inflammatory and Paraproteinemic Neuropathies
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Written Consent to Use the Drug in Children: The Problem of Off-Label Drugs
Current Pharmaceutical Design The Bioenergetics of Isolated Mitochondria from Different Animal Models for Diabetes
Current Diabetes Reviews Immunosuppressive Drugs in HIV Disease
Current Topics in Medicinal Chemistry Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery Central Blood Pressure in Chronic Kidney Disease: Latest Evidence and Clinical Relevance
Current Hypertension Reviews Therapeutic Monitoring of Mycophenolate in Transplantation: Is It Justified?
Current Drug Metabolism Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry The Hepatic Lipidome: A Gateway to Understanding the Pathogenes is of Alcohol-Induced Fatty Liver
Current Molecular Pharmacology Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Nanomaterials and Stem Cell Differentiation Potential: An Overview of Biological Aspects and Biomedical Efficacy
Current Medicinal Chemistry Diffuse Correlation Spectroscopy (DCS): A Diagnostic Tool for Assessing Tissue Blood Flow in Vascular-Related Diseases and Therapies
Current Medical Imaging Aptamers and New Bioreceptors for the Electrochemical Detection of Biomarkers Expressed in Hepatocellular Carcinoma
Current Medicinal Chemistry Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets